The global robotic knee arthroplasty market was valued at USD 1.44 billion in 2025. It is estimated to reach USD 1.66 billion in 2026 and is forecast to grow to USD 7.85 billion by 2036, at a CAGR of 16.8% over 2026-2036. This report provides a detailed assessment of the market, covering procedure volumes and robotic penetration, reimbursement and site of care changes, regulatory clearances and autonomy, commercial placement models, clinical evidence, pricing, the supplier landscape, and future growth opportunities.
The market includes robotic systems that plan implant position and assist bone preparation in knee replacement, the instruments and accessories used in each case, implants supplied specifically for use with these platforms, and planning software and service contracts. It spans total, partial, and revision procedures in hospitals, ambulatory surgical centers, and specialty orthopedic clinics. Conventional knee arthroplasty, the wider knee implant market, navigation and augmented reality systems without robotic bone preparation, hip, shoulder, spine, and soft tissue robotics, preoperative imaging, patient-specific instrumentation made without a robot, and rehabilitation services are excluded.
According to the American Joint Replacement Registry, robotic assistance was used in close to 16.1% of primary total knee arthroplasty procedures in its aggregate 2024 analysis, which means roughly five in six primary knees in the registry were still done without a robot. Payment does not reward the technology: according to the 2026 Medicare rates, CPT 27447 total knee arthroplasty pays USD 13,116 in hospital outpatient departments and USD 9,393 in ambulatory surgical centers, with no extra amount for robotic use. The Centers for Medicare & Medicaid Services also removed 285 musculoskeletal procedures, including the whole CPT 27000 series, from the inpatient-only list for 2026 over a three-year phase-in and added 276 codes to the ambulatory covered procedures list.
Payment neutrality is the main restraint, as facilities receive the same fee whether or not a robot is used, so each system must pay for itself through case throughput, implant terms, and shorter stays. The restraint is sharpest in ambulatory surgical centers, where the lower rate, limited capital budgets, scarce operating room space, and the cost of setup time on a busy list all weigh against a floor-standing system. Demonstrating benefit against a conventional procedure that already has strong long-term registry results and high patient satisfaction is the central challenge, especially for newly cleared platforms that lack the published data of established systems. Low utilization of installed systems is a further challenge, since a robot used for only part of a surgeon's list delivers far less consumable, implant, and service revenue than the placement count suggests.
Miniature and bone-mounted systems for ambulatory settings are the clearest opportunity, together with placement models that need no capital from the buyer, such as implant volume commitments, per-procedure fees, and bundled supply agreements. Imageless systems that avoid the cost, scheduling, and radiation of a preoperative scan, and revision surgery, where distorted anatomy and prior implants make accurate planning hardest, also offer strong openings. Key trends include smaller equipment and shorter setup times, the replacement of capital sales with use-based arrangements, and the acquisition of robotic platforms by implant makers, illustrated by Zimmer Biomet's purchase of Monogram Technologies in October 2025 after Monogram's semi-autonomous knee system received FDA 510(k) clearance in March 2025.
By offering, the robotic knee arthroplasty market is segmented into robotic systems, instruments & accessories, implants used with robotic systems, and software & services. Robotic systems hold the largest share in 2026, reflecting the high capital value of each installation compared with per-case items and the steady addition of new sites to the installed base. Instruments & accessories are expected to post the highest CAGR, as this revenue builds every time a system is used, the installed base keeps consuming items for years after placement, and volume-based and per-procedure contracts move value away from the equipment line. Software & services are now attached to most placements, while implants are counted only where they are supplied specifically for a platform.
By procedure type, the robotic knee arthroplasty market is segmented into total knee arthroplasty, partial knee arthroplasty, and revision knee arthroplasty. Total knee arthroplasty leads in 2026, as it is by far the most common of the three operations and most robotic platforms were designed and cleared for it first. Revision knee arthroplasty is expected to grow at the highest CAGR, because bone loss, old hardware, and altered anatomy make precise planning difficult by conventional means, the number of revisions rises as the implant population ages, and the clinical case is stronger against a complex operation. Partial knee procedures were an early robotic application but remain a limited share of knee replacement and carry a narrower implant range per case.
By system architecture, the robotic knee arthroplasty market is segmented into image-based systems and imageless systems. Image-based systems account for the largest share in 2026, since much of the installed base was built on platforms that plan from a preoperative scan which allows detailed planning before surgery. Imageless systems are expected to register the highest CAGR, as taking measurements during surgery removes the cost, scheduling, and radiation exposure of a separate scan, suits ambulatory facilities, and lowers the total cost of a robotic case where no added payment is available.
By system type, the robotic knee arthroplasty market is segmented into robotic arm-assisted systems, handheld robotic systems, and miniature & bone-mounted systems. Robotic arm-assisted systems lead in 2026, as hospital installations were built on floor-standing arms that carry the highest value per placement. Miniature & bone-mounted systems are expected to grow at the highest CAGR, because they remove the large arm and dedicated room footprint, fit facilities that cannot host a large unit, and cut setup time where operating room minutes are a direct cost; THINK Surgical received FDA 510(k) clearance for a miniature total knee system in 2023. Handheld systems sit between the two, used both by hospitals moving from conventional technique and by ambulatory centers.
By end user, the robotic knee arthroplasty market is segmented into hospitals, ambulatory surgical centers, and specialty orthopedic clinics. Hospitals hold the largest share in 2026, as they have capital budgets, dedicated operating room space, and higher procedure payments, and most of the installed base sits in hospital systems. Ambulatory surgical centers are expected to record the highest CAGR, driven by CMS rule changes that are taking knee replacement off the inpatient-only list and onto the ambulatory covered list, although growth depends on equipment placed without a capital purchase because of the lower ambulatory rate. Specialty orthopedic clinics concentrate high case volumes on a single system and are often early users of volume-based placement arrangements.
North America is set to hold the largest share of the global robotic knee arthroplasty market in 2026, supported by an installed base built over the past decade, high knee replacement volumes, and registry reporting that makes adoption measurable. In the U.S., site of care reform is moving knee replacement into outpatient and ambulatory facilities and shifting demand toward smaller systems and use-based placement models.
Asia-Pacific is expected to grow at the highest CAGR, driven by a small installed base relative to procedure volume, domestic manufacturers in China and South Korea offering systems at lower prices than imported platforms, and national procurement programs that have cut implant prices and raised procedure numbers. China offers the largest part of the regional opportunity, while Japan and South Korea buy mainly through existing hospital procurement routes, and India and Australia add further growth. Adoption in Europe is slower and more evidence-driven, as hospital tenders weigh lifetime cost and national registries feed outcome data into evaluations. Latin America and the Middle East & Africa are concentrated in private hospital groups and a few public referral centers, with Brazil and the Gulf states holding the largest positions.
Orthopedic implant manufacturers rather than robotics specialists lead the robotic knee arthroplasty market, as each major knee implant supplier has built or bought a platform to protect its implant revenue. A smaller set of specialist developers sells systems without a large implant range, and a rising number of Chinese and South Korean manufacturers serve domestic buyers at lower price points. Competitive position rests on the ability to place systems without buyer capital, on setup time and footprint, and on the strength of the linked implant portfolio. Zimmer Biomet's acquisition of Monogram Technologies, completed on October 7, 2025, shows that platforms are being bought outright rather than licensed, leaving few independent developers of scale outside Asia-Pacific.
Key companies profiled in the report include Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Smith & Nephew plc (U.K.), Johnson & Johnson (U.S.), THINK Surgical, Inc. (U.S.), CUREXO, Inc. (South Korea), Corin Group (U.K.), MicroPort Scientific Corporation (China), Beijing Tinavi Medical Technologies Co., Ltd. (China), Longwood Valley MedTech Co., Ltd. (China), and Naton Medical Group (China).
The market includes robotic systems that plan implant position and assist bone preparation in knee replacement, the instruments and accessories used in each case, implants supplied specifically for use with these platforms, and planning software and service contracts. It spans total, partial, and revision procedures in hospitals, ambulatory surgical centers, and specialty orthopedic clinics. Conventional knee arthroplasty, the wider knee implant market, navigation and augmented reality systems without robotic bone preparation, hip, shoulder, spine, and soft tissue robotics, preoperative imaging, patient-specific instrumentation made without a robot, and rehabilitation services are excluded.
According to the American Joint Replacement Registry, robotic assistance was used in close to 16.1% of primary total knee arthroplasty procedures in its aggregate 2024 analysis, which means roughly five in six primary knees in the registry were still done without a robot. Payment does not reward the technology: according to the 2026 Medicare rates, CPT 27447 total knee arthroplasty pays USD 13,116 in hospital outpatient departments and USD 9,393 in ambulatory surgical centers, with no extra amount for robotic use. The Centers for Medicare & Medicaid Services also removed 285 musculoskeletal procedures, including the whole CPT 27000 series, from the inpatient-only list for 2026 over a three-year phase-in and added 276 codes to the ambulatory covered procedures list.
Market Dynamics
The large share of knee replacements not yet converted to robotic assistance is the main driver of the robotic knee arthroplasty market, since procedure volumes are already counted and growth depends on how fast that share is taken rather than on new demand. The shift of knee replacement to hospital outpatient departments and ambulatory surgical centers adds new sites that each represent a first placement, and it favors compact systems that need no dedicated operating room and set up quickly between cases. Recurring revenue from instruments, trackers, single-use components, software, and service agreements means an installed system earns income every time it is used. Implant attachment is a further driver, because a platform works only with the implants validated for it, so a hospital that installs a system effectively chooses its implant supplier, and implant revenue over a placement's life is several times the equipment value.Payment neutrality is the main restraint, as facilities receive the same fee whether or not a robot is used, so each system must pay for itself through case throughput, implant terms, and shorter stays. The restraint is sharpest in ambulatory surgical centers, where the lower rate, limited capital budgets, scarce operating room space, and the cost of setup time on a busy list all weigh against a floor-standing system. Demonstrating benefit against a conventional procedure that already has strong long-term registry results and high patient satisfaction is the central challenge, especially for newly cleared platforms that lack the published data of established systems. Low utilization of installed systems is a further challenge, since a robot used for only part of a surgeon's list delivers far less consumable, implant, and service revenue than the placement count suggests.
Miniature and bone-mounted systems for ambulatory settings are the clearest opportunity, together with placement models that need no capital from the buyer, such as implant volume commitments, per-procedure fees, and bundled supply agreements. Imageless systems that avoid the cost, scheduling, and radiation of a preoperative scan, and revision surgery, where distorted anatomy and prior implants make accurate planning hardest, also offer strong openings. Key trends include smaller equipment and shorter setup times, the replacement of capital sales with use-based arrangements, and the acquisition of robotic platforms by implant makers, illustrated by Zimmer Biomet's purchase of Monogram Technologies in October 2025 after Monogram's semi-autonomous knee system received FDA 510(k) clearance in March 2025.
Segment Analysis
The report analyzes the market by offering, procedure type, system architecture, system type, end user, and geography, helping stakeholders identify the most attractive areas for product development, placement, and investment.By offering, the robotic knee arthroplasty market is segmented into robotic systems, instruments & accessories, implants used with robotic systems, and software & services. Robotic systems hold the largest share in 2026, reflecting the high capital value of each installation compared with per-case items and the steady addition of new sites to the installed base. Instruments & accessories are expected to post the highest CAGR, as this revenue builds every time a system is used, the installed base keeps consuming items for years after placement, and volume-based and per-procedure contracts move value away from the equipment line. Software & services are now attached to most placements, while implants are counted only where they are supplied specifically for a platform.
By procedure type, the robotic knee arthroplasty market is segmented into total knee arthroplasty, partial knee arthroplasty, and revision knee arthroplasty. Total knee arthroplasty leads in 2026, as it is by far the most common of the three operations and most robotic platforms were designed and cleared for it first. Revision knee arthroplasty is expected to grow at the highest CAGR, because bone loss, old hardware, and altered anatomy make precise planning difficult by conventional means, the number of revisions rises as the implant population ages, and the clinical case is stronger against a complex operation. Partial knee procedures were an early robotic application but remain a limited share of knee replacement and carry a narrower implant range per case.
By system architecture, the robotic knee arthroplasty market is segmented into image-based systems and imageless systems. Image-based systems account for the largest share in 2026, since much of the installed base was built on platforms that plan from a preoperative scan which allows detailed planning before surgery. Imageless systems are expected to register the highest CAGR, as taking measurements during surgery removes the cost, scheduling, and radiation exposure of a separate scan, suits ambulatory facilities, and lowers the total cost of a robotic case where no added payment is available.
By system type, the robotic knee arthroplasty market is segmented into robotic arm-assisted systems, handheld robotic systems, and miniature & bone-mounted systems. Robotic arm-assisted systems lead in 2026, as hospital installations were built on floor-standing arms that carry the highest value per placement. Miniature & bone-mounted systems are expected to grow at the highest CAGR, because they remove the large arm and dedicated room footprint, fit facilities that cannot host a large unit, and cut setup time where operating room minutes are a direct cost; THINK Surgical received FDA 510(k) clearance for a miniature total knee system in 2023. Handheld systems sit between the two, used both by hospitals moving from conventional technique and by ambulatory centers.
By end user, the robotic knee arthroplasty market is segmented into hospitals, ambulatory surgical centers, and specialty orthopedic clinics. Hospitals hold the largest share in 2026, as they have capital budgets, dedicated operating room space, and higher procedure payments, and most of the installed base sits in hospital systems. Ambulatory surgical centers are expected to record the highest CAGR, driven by CMS rule changes that are taking knee replacement off the inpatient-only list and onto the ambulatory covered list, although growth depends on equipment placed without a capital purchase because of the lower ambulatory rate. Specialty orthopedic clinics concentrate high case volumes on a single system and are often early users of volume-based placement arrangements.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 17 countries, the GCC countries, and four rest-of-region groups. The regional analysis of the robotic knee arthroplasty market considers procedure volumes, installed base and penetration, payment and site of care rules, procurement practices, and the presence of domestic manufacturers.North America is set to hold the largest share of the global robotic knee arthroplasty market in 2026, supported by an installed base built over the past decade, high knee replacement volumes, and registry reporting that makes adoption measurable. In the U.S., site of care reform is moving knee replacement into outpatient and ambulatory facilities and shifting demand toward smaller systems and use-based placement models.
Asia-Pacific is expected to grow at the highest CAGR, driven by a small installed base relative to procedure volume, domestic manufacturers in China and South Korea offering systems at lower prices than imported platforms, and national procurement programs that have cut implant prices and raised procedure numbers. China offers the largest part of the regional opportunity, while Japan and South Korea buy mainly through existing hospital procurement routes, and India and Australia add further growth. Adoption in Europe is slower and more evidence-driven, as hospital tenders weigh lifetime cost and national registries feed outcome data into evaluations. Latin America and the Middle East & Africa are concentrated in private hospital groups and a few public referral centers, with Brazil and the Gulf states holding the largest positions.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, market share analysis, and benchmarking by installed base and utilization and by placement model and implant attachment. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.Orthopedic implant manufacturers rather than robotics specialists lead the robotic knee arthroplasty market, as each major knee implant supplier has built or bought a platform to protect its implant revenue. A smaller set of specialist developers sells systems without a large implant range, and a rising number of Chinese and South Korean manufacturers serve domestic buyers at lower price points. Competitive position rests on the ability to place systems without buyer capital, on setup time and footprint, and on the strength of the linked implant portfolio. Zimmer Biomet's acquisition of Monogram Technologies, completed on October 7, 2025, shows that platforms are being bought outright rather than licensed, leaving few independent developers of scale outside Asia-Pacific.
Key companies profiled in the report include Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Smith & Nephew plc (U.K.), Johnson & Johnson (U.S.), THINK Surgical, Inc. (U.S.), CUREXO, Inc. (South Korea), Corin Group (U.K.), MicroPort Scientific Corporation (China), Beijing Tinavi Medical Technologies Co., Ltd. (China), Longwood Valley MedTech Co., Ltd. (China), and Naton Medical Group (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global robotic knee arthroplasty market.
- Explains how unconverted procedure share, site of care reform, and implant attachment are shaping growth.
- Assesses the effect of payment neutrality, lower ambulatory rates, and system utilization on placement economics.
- Identifies high-growth opportunities across offering, procedure type, system architecture, system type, end user, and region.
- Tracks miniature, bone-mounted, handheld, and imageless systems and the regulatory status of autonomous technology.
- Benchmarks leading companies by installed base, utilization, placement model, and implant attachment.
- Supports product planning, commercial model design, partnering, acquisition, and market entry decisions for manufacturers, providers, and investors.
Key Questions Answered
- How big is the global robotic knee arthroplasty market today, and how will it grow through 2036?
- What share of knee replacements is already performed with robotic assistance, and how fast can the remainder convert?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do Medicare payment rates and inpatient-only list changes affect equipment placement?
- Which offerings, procedure types, system architectures, system types, and end users will grow the fastest?
- How are per-procedure fees and implant volume commitments replacing capital sales?
- What is the regulatory status of semi-autonomous and fully autonomous knee systems?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how do they compete on placement models and implant portfolios?
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Global Robotic Knee Arthroplasty Market Assessment, by Offering
6. Global Robotic Knee Arthroplasty Market Assessment, by Procedure Type
7. Global Robotic Knee Arthroplasty Market Assessment, by System Architecture
8. Global Robotic Knee Arthroplasty Market Assessment, by System Type
9. Global Robotic Knee Arthroplasty Market Assessment, by End User
10. Global Robotic Knee Arthroplasty Market Assessment, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Stryker Corporation
- Zimmer Biomet Holdings, Inc.
- Smith & Nephew plc
- Johnson & Johnson
- THINK Surgical, Inc.
- CUREXO, Inc.
- Corin Group
- MicroPort Scientific Corporation
- Beijing Tinavi Medical Technologies Co., Ltd.
- Longwood Valley MedTech Co., Ltd.
- Naton Medical Group
